Targeting the PD-1 pathway: a new hope for gastrointestinal cancers

---

Copy For Citation

BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., Dede D. S., YALÇIN B.

CURRENT MEDICAL RESEARCH AND OPINION, vol.33, no.4, pp.749-759, 2017 (SCI-Expanded)

• Publication Type: Article / Review
• Volume: 33 Issue: 4
• Publication Date: 2017
• Doi Number: 10.1080/03007995.2017.1279132
• Journal Name: CURRENT MEDICAL RESEARCH AND OPINION
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.749-759
• Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

Background: VEGF, HER2 and EGFR targeted agents are currently used in gastric, esophageal and colorectal cancers. However, treatment outcomes are still poor in most gastrointestinal (GI) cancers. Immune checkpoints are one of the most promising immunotherapy approaches. In this review article, we aim to discuss the efficacy and safety of anti-PD-1/PD-L1 therapies in GI cancers, including gastric, esophageal and colorectal cancer in published or reported recent studies.